Peptide Aggregation: Causes, Detection, and Prevention

Peptide aggregation is the self-association of peptide chains into ordered or disordered clusters, driven by hydrophobic collapse, backbone hydrogen bonding, or inter-chain β-sheet formation. It happens both in solution and on solid-phase resin, and once it starts, it is the leading cause of stalled couplings, truncated sequences, and irreproducible bioassay data across peptide chemistry.

The single most useful diagnostic move: before troubleshooting reagents or protocols, check whether the problem tracks with amino-acid composition rather than a specific sequence motif. A 2026 Nature Chemistry study found that composition (the ratio of hydrophobic, aromatic, and charged residues) predicts SPPS aggregation better than sequence-pattern models alone. That single insight reframes most troubleshooting: instead of hunting for a “difficult” motif, you look at what the chain is actually made of, and where those residues sit relative to the resin.

Tools like APte and APpe (aggregation-propensity metrics from a 2024 JACS Au study), automated fast-flow platforms like AFPS, and removable tag strategies like ArgTag have turned aggregation from a guessing game into something you can predict, monitor, and fix. Here is what to check first:

• Pull the deprotection UV trace for the failing couplings and look for a broadening or tailing peak, a classic early sign of on-resin aggregation.
• Tabulate the C-terminal 10 to 15 residues and flag aliphatic (Val, Ile, Leu), aromatic (Phe, Trp, Tyr), and positively charged clusters, since aggregation onset commonly concentrates near the resin anchor point.
• Run a small-scale test coupling with a fresh resin lot before scaling up. Resin swelling failures mimic aggregation symptoms but have a different fix.
• Try a low-cost solvent swap (adding DMSO or NMP-to-DCM ratio changes) before reaching for a resin change or a tag strategy.
• Screen for a composition-based mitigation, such as a pseudoproline dipeptide at a high-contribution residue, if the UV trace and sequence review both point to composition rather than a one-off reagent problem.

Key Takeaways

Amino-acid composition, not sequence pattern alone, is the strongest predictor of peptide aggregation in SPPS, and early diagnosis with UV traces beats late-stage reagent troubleshooting every time.

Table of Contents

• What Causes Peptide Aggregation at the Molecular Level
• How to Predict Peptide Aggregation Before You Synthesize
• Detecting and Characterizing Aggregates in the Lab
• Aggregation During Solid-Phase Synthesis: Resin and Chemistry Choices
• Practical Prevention Strategies for Solution-Phase Work
• Troubleshooting Aggregation-Related Synthesis Failures
• Can Peptide Aggregation Be Reversed?
• Why Peptide Aggregation Matters Beyond the Bench
• A Practical Lab Checklist for Aggregation-Prone Peptides
• Where the Field Is Heading
• Sources
• FAQ

What Causes Peptide Aggregation at the Molecular Level

Aggregation is a competition between chain solvation and chain-chain association, and composition tips that balance more than most chemists assume. Hydrophobic and aromatic residues, particularly Val, Ile, Leu, Phe, and Trp, promote inter-chain packing through van der Waals contacts and pi-stacking. Charged residues (Asp, Glu, Lys, Arg) usually counteract this by keeping chains solvated, but charge patterning matters as much as charge count: a block of like charges spread through a sequence behaves differently than the same residues scattered singly.

Protecting groups complicate the picture further. Bulky groups like Trt (trityl) on His, Cys, or Asn, and Pbf on Arg, add steric bulk that can either shield a hydrophobic patch or worsen local crowding depending on where they sit in the chain. The t-Bu-based groups on Ser, Thr, Tyr, Asp, and Glu behave more predictably, but stacking several bulky protecting groups within a short stretch of sequence, especially near the resin, raises aggregation risk regardless of the underlying residue identity.

The 2026 Nature Chemistry composition-vector model validated something practitioners had suspected for years: shuffling a sequence while holding composition constant barely changes aggregation behavior in most SPPS cases. Sequence-pattern searches, the kind that look for a specific “difficult” three or four-residue stretch, miss this. Composition is the stronger signal, and the researchers behind the study confirmed it experimentally using AFPS deprotection UV data across many shuffled variants.

Extrinsic conditions act on top of these intrinsic drivers. In solution, concentration is the most direct lever: aggregation kinetics for many peptides scale non-linearly above a threshold concentration, and diluting a stock solution is often the fastest way to confirm whether a purification or bioassay artifact is concentration-driven. pH shifts change the peptide’s net charge and can push a construct through its isoelectric point, where solubility drops sharply. Ionic strength, solvent polarity, temperature, agitation, and exposure to air-liquid interfaces all modulate the same underlying hydrophobic collapse and hydrogen-bonding network that composition sets up.

On resin, the extrinsic environment is dominated by swelling and solvation of the peptide-resin complex rather than bulk solution conditions. A Merck technical note on SPPS frames most aggregation mitigation as an exercise in improving that solvation, through resin choice, solvent blends, and PEG content, rather than purely a sequence or reagent fix. When resin polarity mismatches the growing peptide’s polarity, chains collapse onto themselves and each other, nucleating β-sheet-like structures that reduce chain mobility and block reagent access to the N-terminus.

That mechanism explains why coupling efficiency crashes suddenly rather than gradually. Once several chains on a resin bead nucleate a β-sheet-like association, the amine termini become sterically buried, and standard coupling reagents cannot reach them at normal rates. This is also why aggregation tends to cluster within roughly 5 to 15 residues of the resin anchor point rather than appearing randomly across a sequence, a pattern the composition-vector researchers documented directly.

Pro Tip: If a synthesis fails at a specific residue every time you repeat it, do not assume it is that residue’s coupling chemistry. Check the cumulative composition of the 10 residues before it first. The failure point is often where accumulated aggregation crosses a threshold, not where the “bad” chemistry lives.

How to Predict Peptide Aggregation Before You Synthesize

Three families of prediction tools now cover most practical needs, and they answer different questions. Composition-vector models tell you whether your overall amino-acid makeup puts a sequence at risk. Transformer-based predictors tell you which positions and residue pairs within the chain contribute most. Classical propensity scales give you a fast, low-resource first pass.

The composition-vector ensemble from the 2026 Nature Chemistry study takes a sequence, converts it to a compositional fingerprint (counts and fractions of residue classes), and outputs an aggregation propensity score along with suggested mitigation positions. It is particularly useful early in project planning, before you have committed to a synthesis route, because it does not require detailed structural modeling.

The transformer-based predictor described in the JACS Au 2024 paper derives first-order (single-residue) and second-order (residue-pair) aggregation rules from a large dataset of short peptides, then reports APte and APpe values, aggregation propensity metrics tied to experimentally validated tetrapeptide and pentapeptide behavior. Because the model was trained and validated across more than 20,000 tetrapeptides according to the companion JACS Au publication, it can flag specific residue pairs that drive aggregation even when the overall composition looks unremarkable. That granularity matters for short, difficult sequences where a single problematic dipeptide junction is the real culprit.

For a quick manual check without specialized software, classical tools like TANGO and AGGRESCAN remain useful references. They score β-aggregation propensity per residue using empirically derived physicochemical parameters, and while they predate the newer composition and transformer approaches, they are fast, widely available, and good for a first-pass sanity check before committing lab time to a formal model.

A practical prediction workflow looks like this:

1. Compute a composition score for your target sequence using a composition-vector approach, flagging any class (hydrophobic, aromatic, charged) that exceeds typical thresholds for your peptide length.
2. Run a transformer-based or APte/APpe assessment if the sequence is short (four to six residues) or if the composition score alone is ambiguous, to identify high-contribution positions.
3. Map the flagged residues against the planned synthesis route, paying particular attention to any high-contribution residue within 15 positions of the resin anchor.
4. Propose targeted interventions at those positions: pseudoproline dipeptide insertion, a protecting-group swap, or, for chronic problem sequences, a removable solubilizing tag.

Pro Tip: Prediction scores are a planning tool, not a guarantee. Validate any flagged high-risk sequence with a small-scale test synthesis and an in-line UV deprotection trace (an AFPS-style monitoring approach) before committing resin, reagents, and days of bench time to the full-length target.

Detecting and Characterizing Aggregates in the Lab

Not every assay answers the same question, and running the wrong one first wastes time. A ranked approach, from fastest to most definitive, keeps troubleshooting efficient.

1. Quick indicators you can check without leaving the fume hood: the shape of the deprotection UV trace (broadening or tailing suggests slowed reagent access), visual resin shrinkage or clumping, and unexpected precipitation during cleavage or workup.
2. Medium-throughput assays for confirming a suspected problem: dynamic light scattering (DLS) to estimate particle size distribution in solution, SEC-HPLC to separate monomer from higher-order species, and SDS-PAGE for larger constructs where aggregates resolve as high-molecular-weight smears.
3. High-resolution characterization once you need definitive structural information: Thioflavin T (ThT) fluorescence for amyloid-like, cross-β fibril structures; circular dichroism (CD) and FTIR for secondary-structure content and β-sheet signatures; transmission electron microscopy (TEM) or atomic force microscopy (AFM) for direct visualization of fibrils or amorphous clusters; and native mass spectrometry for oligomeric state under close-to-native conditions.

Each method carries real caveats. ThT fluorescence is specific to amyloid-type cross-β structures and will give a false negative for amorphous, non-fibrillar aggregates, a distinction that matters because most SPPS-related aggregation is amorphous rather than amyloidogenic. DLS results shift dramatically with concentration and are prone to artifacts from dust or air bubbles at the interface. Detergents and other excipients used to solubilize a sample can themselves interfere with downstream assays, and CD signals from turbid, partially aggregated samples can be misread as legitimate secondary-structure content when they are really light-scattering artifacts.

Sample preparation determines whether you are measuring the peptide or measuring an artifact you created. Filter samples through a low-protein-binding membrane before DLS or SEC-HPLC, handle resin-bound intermediates gently to avoid mechanical shear that mimics aggregation symptoms, exchange buffers gradually rather than through a single large dilution jump, and avoid extreme dilutions right before an assay since some aggregates dissociate reversibly and will give you a false negative if you dilute past their concentration threshold.

Which method you reach for also depends on where the problem lives. SPPS-resin aggregation shows up fastest in the UV deprotection trace and resin appearance, so start there and confirm with a small-scale cleavage plus LC-MS. Solution-phase aggregation in a purified peptide or a bioassay sample calls for DLS or SEC-HPLC first, escalating to ThT, CD, or TEM only if you need to characterize aggregate morphology for a publication or a mechanistic question.

Aggregation During Solid-Phase Synthesis: Resin and Chemistry Choices

Resin selection sets the baseline solvation environment for the entire synthesis, and it is one of the highest-leverage decisions you make before the first coupling. Polystyrene-based resins like TentaGel swell well in a range of organic solvents and work for most standard sequences, but their moderate polarity can leave hydrophobic-rich or aggregation-prone peptides poorly solvated as the chain grows. PEG-based resins such as ChemMatrix and NovaPEG offer higher polarity and better swelling in polar aprotic and even some aqueous-compatible solvent systems, which generally improves outcomes for difficult, aggregation-prone targets, though ChemMatrix supply has faced periodic shortages that researchers should account for when planning long projects. Polyacrylamide-based Li-resins provide another polar alternative, particularly useful when a project needs consistent performance across highly charged or highly polar sequences where PEG-resin availability is a constraint.

Tag-based strategies address aggregation at its source rather than compensating for it with solvent chemistry. The ArgTag approach, a C-terminal hexa-arginine extension, was shown in an experimental aggregation-suppression study to delay or suppress aggregation across multiple resin types and loading densities during AFPS and preparative-scale synthesis. Because arginine residues are strongly charged and hydrophilic, the tag keeps the growing chain solvated through the aggregation-prone middle stretch of synthesis. Once synthesis and cleavage are complete, the tag is removed enzymatically with Carboxypeptidase B under mild aqueous conditions, a step validated across resin types in the same study, leaving the native sequence intact without a chemical deprotection step that could damage sensitive side chains. Related SynTag strategies follow the same logic: attach a solubilizing element during the hard part of synthesis, then remove it cleanly once the aggregation risk has passed.

Backbone surrogates offer a complementary, non-removable fix. Pseudoproline dipeptides, and Dmb or Hmb-protected residues, introduce a temporary kink or steric disruption into the backbone that prevents the local hydrogen-bonding network a β-sheet needs to nucleate. The Merck technical note recommends inserting these surrogates every three to five residues within a known problem stretch, particularly at the same 5 to 15-residue window from the resin anchor point where composition-driven aggregation tends to concentrate. Because the surrogate reverts to the native residue on cleavage (or, in the Dmb/Hmb case, on final deprotection), you get the mitigation without an extra removal step, at the cost of slightly more complex building-block sourcing and cost per coupling.

Pro Tip: When scaling a synthesis that worked at small scale, run an in-line UV monitoring pass (an AFPS-style deprotection trace) at the target production scale before committing a full resin batch. Aggregation that was invisible at 0.1 mmol scale can appear at 5 mmol scale simply because local peptide density on the resin bead changes with loading.

Practical Prevention Strategies for Solution-Phase Work

Once a peptide is off the resin, the tools shift from synthesis chemistry to formulation science, and the effective interventions differ mainly in how easy they are to implement in a typical academic lab and how much they interfere with downstream analysis.

pH and ionic strength optimization is the highest-value, lowest-cost first step. Moving a peptide’s working pH away from its isoelectric point restores net charge and electrostatic repulsion between chains, and a 2023 Pharmaceutics review lists buffer selection alongside pH adjustment as a primary formulation lever for reducing aggregation and other physical instability pathways. Co-solvents such as controlled amounts of DMSO or acetonitrile can improve solubility for hydrophobic-rich peptides during handling, though they must be removed or accounted for before any cell-based assay. Polysorbates (surfactants like Tween 20 or Tween 80) reduce aggregation driven by air-liquid interface exposure and mechanical agitation, a common problem during repeated freeze-thaw cycles or vigorous vortexing.

PEGylation and extremolyte excipients sit at different points on the reversibility spectrum. Extremolytes like trehalose and ectoine are non-covalent, fully reversible stabilizers that work by preferential exclusion, they get pushed away from the peptide surface, favoring the compact, non-aggregated conformation, and they wash out cleanly during dialysis or buffer exchange. PEGylation, by contrast, is a covalent modification that permanently increases hydrodynamic size and shields aggregation-prone surfaces, but it changes the molecule itself and complicates any assay or characterization step that assumes native molecular weight.

Sequence-level fixes belong in this same toolkit when the peptide is being synthesized for repeated experiments rather than a one-off assay. Introducing an additional Asp or Glu residue at a solvent-exposed position, or engineering charge patterning to break up a hydrophobic cluster, permanently reduces aggregation risk but changes the molecule and requires re-validation of biological activity.

The trade-off between removable and irreversible solutions runs through nearly every choice in this section. A removable solubilizing tag or a reversible excipient like trehalose preserves the native final product for characterization and biological testing. PEGylation and permanent sequence changes solve the aggregation problem more durably but at the cost of altering what you are ultimately studying, a distinction worth deciding on deliberately before you commit a batch to one approach or the other.

Troubleshooting Aggregation-Related Synthesis Failures

When a coupling stalls or crude purity collapses, work through diagnosis before intervention. Jumping straight to a fix without confirming the cause wastes reagents and, worse, can mask the real problem for the next synthesis attempt.

1. Pull the deprotection UV trace for the failing cycle and the several cycles before it. A gradually broadening or tailing peak points to aggregation building over several residues rather than a single bad coupling.
2. Inspect the resin visually. Shrinkage, clumping, or a change in bead color under the microscope can indicate poor swelling or solvation collapse independent of aggregation.
3. Run a ninhydrin or TNBS test on a small resin sample to quantify free amine content and confirm whether the coupling actually failed or simply proceeded slower than expected.
4. Cleave a small aliquot and run LC-MS to characterize the crude product directly, checking for truncations, deletions, or a broad, poorly resolved peak consistent with heterogeneous aggregated species.
5. If aggregation is confirmed, choose a targeted intervention rather than a blanket fix: backbone protection (pseudoproline or Dmb/Hmb) at the implicated residues, a resin swap to a more polar PEG-based option, reduced resin loading to lower local peptide density, or, for chronic problem sequences, an ArgTag insertion.
6. Verify the fix with a test coupling before committing to full-scale re-synthesis, using an activated amino acid fluoride or a fresh UV trace to confirm improved conversion at the previously problematic residue.

A checklist worth running before any re-attempt:

• Small-scale cleavage plus LC-MS on the failed synthesis, not just the final crude product.
• In-line UV trace review, if your synthesizer supports it, across the full sequence rather than just the failure point.
• A test coupling with an activated amino acid fluoride at the implicated position to confirm whether reactivity or accessibility is the limiting factor.
• A fresh resin lot control, since batch-to-batch swelling variation can produce symptoms indistinguishable from aggregation.

One misdiagnosis shows up constantly: adding extra equivalents of activated amino acid or repeating the coupling cycle rarely restores conversion once aggregation has set in. As the JACS Au researchers observed, β-sheet-like inter-chain interactions physically reduce chain accessibility and mobility on the resin bead. More reagent cannot fix a steric and conformational problem, and throwing extra equivalents at it usually just burns material while the real issue, chain packing, goes unaddressed.

Can Peptide Aggregation Be Reversed?

Reversibility depends entirely on what kind of aggregate you are dealing with. Non-covalent aggregates, held together by hydrogen bonding, hydrophobic packing, or electrostatic interactions, can often be disaggregated with the right conditions. Covalent aggregates, formed through disulfide crosslinking, oxidation-driven crosslinks, or other chemical bonds, generally cannot be reversed without breaking the bonds that hold them together, which usually damages the peptide itself.

Ranked from gentlest to most aggressive, disaggregation approaches include:

• Dilution and mild sonication, the first thing to try for suspected concentration-dependent, non-covalent aggregates, since some assemblies dissociate simply by dropping below their critical aggregation concentration.
• Chaotropic agents like urea or guanidine hydrochloride, which disrupt hydrogen bonding and hydrophobic interactions at higher concentrations, useful for stubborn non-covalent aggregates but requiring careful removal before downstream bioassays.
• Detergent-assisted solubilization, using mild non-ionic detergents to disrupt hydrophobic packing without fully denaturing the peptide, a middle-ground option between dilution and chaotropes.
• Mild enzymatic approaches, appropriate mainly for tag-based aggregation control rather than general disaggregation. Enzymatic removal of the ArgTag with Carboxypeptidase B, for example, addresses aggregation at its structural source rather than dissolving an already-formed aggregate.

A rapid-screen protocol for a suspected disaggregation attempt: take a small aliquot of the aggregated material, titrate a chaotropic agent in small concentration increments, and monitor the response by DLS or SEC-HPLC at each step. This tells you both whether the aggregate is reversible and the minimum chaotrope concentration needed, information you need before scaling any disaggregation attempt to a full sample.

Composition-informed inhibitors add another layer worth knowing about. A 2024 Chemistry study showed that peptide-based aggregation inhibitors derived from αB-crystallin work by targeting composition-level molecular determinants, aromaticity, flexibility, and aliphatic content, allowing a single inhibitor design approach to work against both amorphous and amyloid-type aggregation mechanisms at substoichiometric concentrations. That is a meaningfully different strategy than dissolving an aggregate after the fact: it prevents nucleation in the first place by engaging the same compositional drivers this entire guide has centered on.

Pro Tip: Chaotropes and detergents both interfere with common downstream assays, urea suppresses ionization efficiency in mass spectrometry, and detergents can produce false signals in ThT fluorescence. Always plan a clean buffer-exchange or dialysis step before running any post-disaggregation characterization.

Why Peptide Aggregation Matters Beyond the Bench

Amyloid-beta (Aβ42), a 42-residue fragment of the amyloid precursor protein, is the textbook example of biologically consequential aggregation. According to a StatPearls clinical overview, Aβ42 readily forms oligomers and fibrils and is classically associated with the extracellular plaques found in Alzheimer’s disease. What makes Aβ42 instructive for peptide chemists generally, beyond its clinical relevance, is how sensitive its biological activity is to aggregation state: monomeric, oligomeric, and fibrillar Aβ42 behave as functionally distinct species in cell-based assays, not just different physical forms of the same molecule.

That sensitivity is exactly what makes lab-induced aggregation artifacts so dangerous for interpretation. A peptide that partially aggregates during reconstitution, storage, or handling can produce inconsistent activity readouts across replicate experiments, not because the biology is genuinely variable, but because each aliquot contains a different, uncontrolled mixture of monomer and aggregate. Researchers working with any aggregation-prone peptide, not just Aβ, should treat unexplained assay variability as a hypothesis-generating signal to check aggregation state before concluding the biological effect itself is inconsistent.

Orthogonal confirmation is the only reliable safeguard here. No single assay, ThT fluorescence, electron microscopy, or mass spectrometry, tells the whole story on its own. ThT confirms cross-β amyloid structure but says nothing about oligomeric intermediates that lack that specific fold. Electron microscopy shows morphology directly but at a single time point and often after sample preparation steps that can themselves alter aggregation state. Mass spectrometry, especially native MS, can capture oligomeric mass distributions but requires careful method development to avoid disrupting non-covalent assemblies during ionization. Combining at least two of these methods before drawing a conclusion about a biologically active aggregate is standard practice for a reason: each method’s blind spot is covered by a different one’s strength.

A Practical Lab Checklist for Aggregation-Prone Peptides

Reproducibility in aggregation-prone peptide work comes down to documentation as much as chemistry. A synthesis that “worked” without a recorded UV trace, exact solvent ratio, or resin lot number is not reproducible even if it succeeded once.

Recommended supply categories to keep on hand:

• A polar, high-swelling resin option (PEG-based or polyacrylamide-based) in addition to your standard polystyrene stock, for aggregation-prone targets flagged during prediction screening.
• A documented solvent blend library (DMSO, NMP, DCM ratios) with records of which blends improved conversion for past difficult sequences.
• Pseudoproline dipeptide building blocks and Dmb/Hmb-protected residues stocked for common problem motifs in your lab’s typical target classes.
• Carboxypeptidase B or an equivalent enzymatic reagent on hand if your lab uses ArgTag or similar removable-tag strategies.
• Gentle handling consumables, low-protein-binding filters, appropriately sized vials to avoid excessive headspace agitation, and storage conditions that minimize freeze-thaw cycling.

Quality-control steps worth building into standard operating procedure include a small-scale test cleavage with LC-MS before any full-scale synthesis of a new or flagged-risk sequence, archived in-process UV and deprotection traces for every synthesis run rather than only the failed ones, and Certificate of Analysis verification with batch-trace documentation for every purchased peptide or reagent lot used in the study. Working with batch-traced, COA-verified peptides removes one major variable from aggregation troubleshooting: you can rule out lot-to-lot raw material inconsistency before assuming the problem is mechanistic.

Minimum metadata to record for every synthesis or aggregation-related assay: resin type and lot number, resin loading (mmol/g), the full protecting-group scheme, exact solvent blend ratios by volume, reaction temperature, agitation method and speed, and the specific UV trace or LC-MS file associated with that run. Labs that skip this step routinely lose the ability to explain, months later, why one batch of a “known-difficult” sequence worked and another did not.

For labs building out a broader procurement and QC framework, the Complete AminoVault Peptide Guide covers testing standards and product categories in more depth, and the Peptide Guide for Researchers and Clinicians walks through SPPS process improvements aimed specifically at limiting aggregation during synthesis.

Where the Field Is Heading

The shift from sequence-pattern intuition to composition-based and transformer-derived prediction is the most consequential change in aggregation research over the past two years, and it changes how a synthesis should be planned from day one. Instead of discovering aggregation empirically at residue 23 of a 30-mer, a composition score or an APte/APpe assessment run before the first coupling can flag the risk and point to a specific mitigation position. That does not eliminate the need for careful bench work, prediction models still need experimental validation against an actual UV trace or LC-MS result, but it moves the decision point earlier, when interventions like pseudoproline insertion or tag design are cheap to implement.

I think the community would benefit from more open sharing of raw AFPS UV traces alongside standard test sequences, the way structural biologists share raw diffraction data. Right now, most aggregation data lives in supplementary information as summary statistics, and the transformer and composition models that are advancing this field fastest are the ones built on the largest, most granular experimental datasets. A lab that saves and shares its raw deprotection traces for both successful and failed syntheses contributes more to solving this problem field-wide than one more optimized protocol ever will.

Sources

• Amino acid composition drives aggregation during peptide synthesis
• Aggregation rules of short peptides | JACS Au
• Designing formulation strategies for enhanced stability of therapeutic peptides in aqueous solutions: A review
• Peptide inhibitors acting on early aggregation stages — composition determinants (Chemistry, 2024)

Readers building out full experimental protocols should also consult the supplementary information and experimental sections of the cited papers directly. That is where the actual solvent ratios, resin loading numbers, and UV trace acquisition parameters live.

FAQ

What Is Peptide Aggregation?

Peptide aggregation is the self-association of peptide chains into ordered (amyloid-like, cross-β) or disordered (amorphous) clusters, driven by hydrophobic collapse and backbone hydrogen bonding, occurring both during solid-phase synthesis and in solution.

What Is the 2 Peptide Rule?

The term is not a formally established standard in the peptide chemistry literature; if you encountered it referencing dipeptide-level interactions, that likely refers to second-order (residue-pair) aggregation contributions described in the JACS Au transformer model, where specific adjacent residue pairs, not single residues, drive aggregation propensity.

Can Peptide Aggregation Be Reversed?

Non-covalent aggregates, formed through hydrophobic packing or hydrogen bonding, often respond to dilution, mild sonication, chaotropic agents, or detergent-assisted solubilization, while covalent aggregates formed through crosslinking generally cannot be reversed without damaging the peptide.

What Peptides Are Linked to Alzheimer’s Disease?

Amyloid-beta, particularly the 42-residue fragment Aβ42, is the peptide most closely associated with Alzheimer’s disease, forming oligomers and fibrils that accumulate as the extracellular plaques characteristic of the condition, according to a StatPearls clinical overview.

Where Does Aggregation Typically Start During SPPS?

Aggregation commonly originates within roughly 5 to 15 residues of the resin anchoring point, which is why early-elaboration interventions like C-terminal tags or backbone surrogates tend to outperform fixes applied later in the synthesis.

Recommended

• Examples of Peptide Impurities: A Researcher’s Guide
• The Peptide Guide for Researchers and Clinicians